Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
♫ Thursday, January 25th, 2024Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of December 31, 2023:
Excerpt from:
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux